In our study, the large cohort with 2766 samples proved apparent statistically significant difference between SPAG5-high and SPAG5-low expressions in ER+, but not ER- breast cancer, meaning that the expression level of SPAG5 could serve as a survival predictor in ER+ rather than ER- breast cancer patients. The gene discussed is SPAG5; the disease is breast cancer.